The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Replacement - Form 8 (OPD) (Pfizer)

21 May 2014 11:49

RNS Number : 6933H
Pfizer Inc
21 May 2014
 

FORM 8 (OPD)

 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

 

AMENDMENT - CHANGES TO SECTION 3.2

 

1. KEY INFORMATION

 

(a) Identity of the party to the offer making the disclosure:

Pfizer Inc. ("Pfizer")

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

N/A

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

AstraZeneca PLC

(d) Is the party to the offer making the disclosure the offeror or the offeree?

Offeror

(e) Date position held:

9 May 2014

(f) Has the party previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

Yes, Pfizer Inc.

 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 

Class of relevant security:

 

Ordinary Shares

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

Nil

Nil

(2) Derivatives (other than options):

Nil

Nil

(3) Options and agreements to purchase/sell:

Nil

Nil

 

TOTAL:

Nil

Nil

 

 

(b) Rights to subscribe for new securities

 

Class of relevant security in relation to which subscription right exists:

None

Details, including nature of the rights concerned and relevant percentages:

N/A

 

 

(c) Irrevocable commitments and letters of intent

 

Details of any irrevocable commitments or letters of intent procured by the party to the offer making the disclosure or any person acting in concert with it (see Note 3 on Rule 2.11 of the Code):

 

None.

 

 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

Details of any interests, short positions and rights to subscribe of any person acting in concert with the party to the offer making the disclosure:

 

See below

 

 

3.1 Pfizer Directors

 

Name of Director

Number of Ordinary Shares[1] held

Percentage of total issued ordinary shares (excluding treasury shares)

Stephen W. Sanger

161

0.00%

 

 

3.2 Advisers to Pfizer [2]

 

J.P. Morgan (J.P. Morgan Securities plc and J.P. Morgan Trust Company of Delaware)

 

Class of relevant security:

 

Ordinary Shares

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

52,606

0.00%

Nil

(2) Derivatives (other than options):

Nil

Nil

(3) Options and agreements to purchase/sell:

Nil

Nil

 

TOTAL:

52,606

0.00%

Nil

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

 

None.

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

 

None.

 

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

No

Supplemental Form 8 (SBL)

No

 

 

Date of disclosure:

12 May 2014

Contact name:

Chris Dickinson

Geoff Iles

Telephone number:

+44 (0) 207 134 7302

+44 (0) 207 995 1930

 


[1] Comprises AstraZeneca ordinary shares held by Stephen W. Sanger 's close relatives, whether directly or in trust (to his knowledge after inquiry).

[2] The information in this section was provided to Pfizer by the relevant adviser

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FEEBFLFLZEFZBBL
Date   Source Headline
15th Jan 20217:00 amRNSImfinzi new dosing approved in EU
6th Jan 20217:00 amRNSFarxiga granted US Priority Review for CKD
4th Jan 20213:00 pmRNSTotal Voting Rights
4th Jan 20217:00 amRNSAtacand divestment in over 70 countries completed
30th Dec 20207:00 amRNSAstraZeneca’s COVID-19 vaccine authorised in UK
29th Dec 20207:00 amRNSLynparza approved in Japan for three cancers
21st Dec 20207:05 amRNSTagrisso approved in the US for early lung cancer
21st Dec 20207:00 amRNSUpdate on US regulatory review of roxadustat
17th Dec 20204:00 pmRNSDirector/PDMR Shareholding
16th Dec 20206:15 pmRNSDirector/PDMR Shareholding
15th Dec 20207:00 amRNSImfinzi new dose receives positive EU CHMP opinion
14th Dec 20207:05 amRNSTrastuzumab deruxtecan positive CHMP
14th Dec 20207:00 amRNSTrixeo Aerosphere approved in the EU for COPD
14th Dec 20207:00 amRNSAstraZeneca to acquire Alexion Pharmaceuticals Inc
1st Dec 20203:00 pmRNSTotal Voting Rights
1st Dec 20203:00 pmRNSBlock listing Interim Review
1st Dec 20207:00 amRNSCrestor to be divested to Grünenthal in Europe
30th Nov 20207:00 amRNSForxiga approved in Japan for heart failure
23rd Nov 20207:00 amRNSAZD1222 vaccine effective against COVID-19
20th Nov 20207:00 amRNSImfinzi new dosing approved in the US
10th Nov 20207:00 amRNSTezepelumab Phase III trial met primary endpoint
9th Nov 20207:00 amRNSCalquence approved in the EU for CLL
6th Nov 20207:00 amRNSBrilinta approved in the US in stroke
5th Nov 20207:15 amRNSLynparza approved in the EU for wider ovarian use
5th Nov 20207:10 amRNSLynparza approved in the EU for prostate cancer
5th Nov 20207:05 amRNSForxiga approved in the EU for heart failure
5th Nov 20207:00 amRNSAZN: Year-to-date and Q3 2020 results
2nd Nov 20203:00 pmRNSTotal Voting Rights
30th Oct 20207:00 amRNSAtacand to be divested in more than 70 countries
29th Oct 20207:00 amRNSDirectorate Change
28th Oct 20207:03 amRNSEnhertu US Priority Review in gastric cancer
28th Oct 20207:00 amRNSForxiga CV outcomes benefit approved in China
20th Oct 20207:00 amRNSTagrisso adjuvant lung cancer US Priority Review
19th Oct 20207:00 amRNSForxiga HF receives positive CHMP opinion
19th Oct 20207:00 amRNSTrixeo Aerosphere receives positive CHMP opinion
12th Oct 20207:00 amRNSCOVID-19 antibodies advance and get US funding
2nd Oct 202011:19 amRNSHolding(s) in Company
2nd Oct 20207:00 amRNSFarxiga granted US BTD in chronic kidney disease
1st Oct 20203:00 pmRNSTotal Voting Rights
25th Sep 20207:00 amRNSDirectorate Change
21st Sep 20207:05 amRNSLynparza EU recommendation in prostate cancer
21st Sep 20207:00 amRNSLynparza EU recommendation in ovarian cancer
21st Sep 20207:00 amRNSTagrisso reduced early lung cancer brain recurrenc
10th Sep 20207:01 amRNSAstraZeneca to list all US securities on Nasdaq
10th Sep 20207:00 amRNSFasenra PhIII OSTRO trial met co-primary endpoints
1st Sep 20203:00 pmRNSTotal Voting Rights
1st Sep 20207:00 amRNSImfinzi approved in EU for small cell lung cancer
1st Sep 20207:00 amRNSFarxiga reduces CKD progression and risk of death
25th Aug 20207:00 amRNSPh I trial begins for COVID-19 monoclonal antibody
21st Aug 20207:00 amRNSImfinzi approved in Japan for SCLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.